Immune checkpoint inhibitors (ICIs) exert antitumor effects by inhibiting programmed cell death-1 (PD-1) and programmed cell death ligand (PD-L1), which regulate tumor immune tolerance1,2. This evidence concerns the gene PDCD1 and neoplasm.